Bladder Cancer
Specialty Channel

Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
The FDA approved for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
The FDA extended the indication of gemtuzumab ozogamicin to include newly diagnosed CD33-positive AML in patients aged 1 month and older.
True or false: Teratoma is a prognostic factor in patients with metastatic testicular germ cell tumors.

News

Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
The FDA approved for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
The FDA extended the indication of gemtuzumab ozogamicin to include newly diagnosed CD33-positive AML in patients aged 1 month and older.

Interactive Features

What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
Stay in the know.
OncNet Newsletter